News

Morning Read: Better treatment for sepsis, ideas for managing doctor/hospital partnerships

Spectral Diagnostics Inc. is conducting a Phase III pivotal multicenter study in the U.S. and Canada to see if its new treatment can reduce deaths from sepsis. Toraymyxin removes circulating endotoxin from the bloodstream and in one trial reduced mortality from 53 to 32 percent. Chuck Peck, MD, CEO of Health Inventures explains three models […]

Spectral Diagnostics Inc. is conducting a Phase III pivotal multicenter study in the U.S. and Canada to see if its new treatment can reduce deaths from sepsis. Toraymyxin removes circulating endotoxin from the bloodstream and in one trial reduced mortality from 53 to 32 percent.

Chuck Peck, MD, CEO of Health Inventures explains three models for hospital/doctor partnerships and 10 rules for successful integration of physician alignment initiatives. The crucial rules include over-communicating, maintaining aligned incentives, and understanding the price of equity.

CardioKinetix has promising news from a small study of its implantable device that helps the heart beat more efficiently after damage from a heart attack. In the group of 31 patients, 16 percent of the patients died or had to be hospitalized within one year of getting the heart failure implant, compared to historic studies that show about 40 percent of people who have had heart attacks who have the same result.

Kythera Biopharmaceuticals will use its venture cash and IPO profits to help Americans solve the problem of the dreaded double chinATX-101 is an injectable drug designed to remove submental fat.

The latest fund from Kleiner Perkins Caufield Byers will focus on investments in early-stage digital consumer and enterprise, green technology, and life sciences companies. KPCB closed on a $525 million round for its fifteenth venture fund.